md phd rug

Applying to MD-PhD Programs

New section.

Are you considering a MD-PhD program? Here the basics about applying to MD-PhD programs to help you get started.

The MD-PhD dual degree training prepares you for a career that is busy, challenging, and rewarding, and offers opportunities to do good for many people by advancing medical science, developing new diagnostics and treatments for diseases, and pushing back the boundaries of the unknown.

How do I know if a combined program is right for me?

MD-PhD programs are specifically designed for those who want to become physician-researchers, also known as physician-scientists. Graduates of MD-PhD programs often go on to become faculty members at medical schools, universities, and research institutes such as the National Institutes of Health (NIH).

MD-PhD program students are being prepared for careers in which they will spend most of their time doing research in addition to caring for patients. It is critical that applicants have a passion for doing both—most MD-PhD graduates feel strongly that they would not be fulfilled by only pursuing medicine or science.

How do I apply?

Nearly all MD-PhD programs participate in the application process via the American Medical College Application Service® (AMCAS®) . On the AMCAS application, students designate themselves as MD-PhD applicants and complete two additional essays: one related to why they are interested in MD-PhD training, and the other highlighting their significant research experiences.

What schools offer this type of program?

Nationwide, there are more than 90 MD-PhD programs affiliated with medical schools. The National Institute of General Medical Sciences (NIGMS) supports Medical Scientist Training Programs or MSTPs. They currently provide training grants that partially support MD-PhD programs at 49 degree-granting institutions. You can see which schools offer MD-PhD degrees in the  Medical School Admission Requirements  profiles under “Combined Degrees and Special Programs.” You can also review  Individual MD-PhD Program Information for Prospective Applicants  for easy access to individual MD-PhD program websites.

How long does it take?

Students enter an integrated curriculum that typically takes seven to eight years to complete. During which time, they satisfy the full requirements for both the MD and the PhD degrees.

What kind of work can I do? How much time is spent as an MD? As a researcher?

According to a  study of MD-PhD program outcomes , nearly 80 percent of graduates are following career paths consistent with the goals of their training, including working as full-time faculty in academic medical centers or for the NIH, research institutes, industry, and federal agencies. Those in academia, spend between 50 and 80 percent of their time conducting research, though this can vary by specialty. Their research may be lab-based, translational, or clinical. The remaining time is often divided between clinical service, teaching, and administrative activities.

MD-PhD Application Timeline

AMCAS application opens:  May preceding the year of expected entry Applicants interviewed:  October–March Final decisions sent to applicants:  December–March Applicants revisit program(s) to decide where to matriculate:  March–April MD-PhD programs start:  June–August

• Like AAMC Pre-Med
• Follow @AAMCpremed

Information on how to become a research physician, also known as a physician-investigator or a physician-scientist.

A Personal Plea to Premeds

Trisha Kaundinya | January 13, 2021

When I was in college, I was in a premed “bubble” a lot of the time. I took many of my courses and labs alongside hundreds of other aspiring physicians. I would see the same people throughout my academic day, and sometimes even outside of the lecture hall. Because of this, I unintentionally overheard conversations […]

Get important information, resources, and tips to help you on your path to medical school—delivered right to your inbox each month.

• Clinical Physics
• Translational Physics
• Proton Engineers
• Physics Residents
• Information Technology
• Past Members

Certification

Therapeutic Physics, American Board of Radiology

AAPM Jack Fowler Junior Investigators Award, 2004

Publications in Radiation Oncology and Medical Physics

Yan S, Lu HM, Flanz J, Adams J, Trofimov A, Bortfeld T. Reassessment of the necessity of the proton gantry:  analysis of beam orientations from 4332 treatments at the F.H. Burr proton center over the past 10 years. International Journal of Radiation Oncology Biology Physics 2016

Moteabbed M, Trofimov A, Sharp GC, Wang Y, Zietman AL, Efstathiou JA, Lu HM. A prospective comparison of the effects of interfractional variations on proton therapy and IMRT for prostate cancer. International Journal of Radiation Oncology Biology Physics 2016

Patel AV, Lane AM, Morrison MA, Trofimov AV, Shih HA, Gragoudas ES, Kim IK. Visual Outcomes after Proton Beam Irradiation for Choroidal Melanomas Involving the Fovea. Ophthalmology 2015 

M oteabbed M, Sharp GC, Wang Y, Trofimov A, Efstathiou JA, Lu HM. Validation of a deformable image registration technique for cone beam CT-based dose verification. Medical Physics 2015;42:196-205

Cheney MD, Chen YL, Lim R, Winrich BK, Grosu AL, Trofimov AV, Depauw N, Shih HA, Schwab JH, Hornicek FJ, DeLaney TF. 18F-FMISO PET/CT visualization of tumor hypoxia in patients with chordoma of the mobile and sacrococcygeal spine. International Journal of Radiation Oncology Biology Physics 2014

Safai S, Trofimov A, Adams JA, Engelsman M, Bortfeld T. The rationale for intensity-modulated proton therapy in geometrically challenging cases. Physics in Medicine and Biology 2013;58:6337-6353.

Giantsoudi D, Grassberger C, Craft D, Niemierko A, Trofimov A, Paganetti H. Linear energy transfer (LET)-Guided Optimization in intensity modulated proton therapy (IMPT): feasibility study and clinical potential. International Journal of Radiation Oncology Biology Physics 2013;87:216-222.

Wang. Y, Efstathiou JE, Lu H, Sharp GC, Trofimov A. Hypofractionated proton therapy for prostate cancer: dose delivery uncertainty due to inter-fractional motion. Medical Physics 2013;40:071714

Zeng C, Giantsoudi D, Grassberger C, Goldberg S, Niemierko A, Paganetti H, Efstathiou JA, Trofimov A.  Maximizing the biological effect of proton dose delivered with scanned beams via inhomogeneous daily dose distributions. Medical Physics 2013;40:051708.

De Amorim Bernstein K, Sethi R, Trofimov A, Zeng C, Fullerton B, Yeap BY, Ebb D, Tarbell NJ, Yock TI, Macdonald SM. Early clinical outcomes using proton radiation for children with central nervous system atypical teratoid rhabdoid tumors. International Journal of Radiation Oncology Biology Physics 2013;86:114-20.

Trofimov A, Unkelbach J, DeLaney TF, Bortfeld T. Visualization of a variety of possible dosimetric outcomes in radiation therapy using dose-volume histogram bands. Practical Radiation Oncology 2012;2:164-171. 

Chen W, Unkelbach J, Trofimov A, Madden T, Kooy H, Bortfeld T, Craft D. Including robustness in multi-criteria optimization for intensity-modulated proton therapy. Physics in Medicine and Biology 2012;57:591-608.

Wang Y, Efstathiou J, Sharp G, Lu HM, Ciernik IF, Trofimov A. Evaluation of the dosimetric impact of inter-fractional anatomical variations on prostate proton therapy using daily in-room CT images. Medical Physics 2011

Grassberger C, Trofimov A, Lomax A, Paganetti H. Variations in linear energy transfer within clinical proton therapy fields and the potential for biological treatment planning. International Journal of Radiation Oncology Biology Physics 2011

Trofimov A, NguyenPL, EfstathiouJA, Wang Y, LuHM, EngelsmanM, MerrickS, ChengCW, WongJR, ZietmanAL. Interfractional variations in the set-up of pelvic bony anatomy and soft tissue, and their implication on the delivery of proton therapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics 2011; 80:928-937.

Ding A, Gu J, Trofimov A, Xu XG.  Monte Carlo calculation of imaging doses from diagnostic multi-detector CT and kilovoltage cone-beam CT as part of prostate cancer treatment plans. Medical Physics 2010; 37:6199-6204.

MacDonald SM, Trofimov A, Safai S, Adams J, Fullerton B, Ebb D, Tarbell NJ, Yock T. Proton Radiotherapy for Pediatric Central Nervous System Germ Cell Tumors: Early Clinical Outcomes. International Journal of Radiation Oncology Biology Physics 2011; 79:121-129

Nguyen PL, Chen RC, Hoffman KE, Trofimov A, Efstathiou JA, Coen JJ, Shipley WU, Zietman AL, Talcott JA. Rectal Dose-Volume Histogram Parameters Are Associated with Long-Term Patient-Reported Gastrointestinal Quality of Life After Conventional and High-Dose Radiation for Prostate Cancer: A Subgroup Analysis of a Randomized Trial. International Journal of Radiation Oncology Biology Physics 2010; 78:1081-5

Suit H, Delaney T, Goldberg S, Paganetti H, Clasie B, Gerweck L, Niemierko A, Hall E, Flanz J, Hallman J, Trofimov A. Proton vs carbon ion beams in the definitive radiation treatment of cancer patients. Radiotherapy and Oncology 2010; 95:3-22.

Kooy HM, Clasie BM, Lu HM, Madden TM, Bentefour H, Depauw N, Adams JA, Trofimov AV, Demaret D, Delaney TF, Flanz JB. A case study in proton pencil-beam scanning delivery. International Journal of Radiation Oncology Biology Physics. 2010; 76:624-30.

Efstathiou JA, Trofimov AV, Zietman AL. Life, liberty, and the pursuit of protons: an evidence-based review of the role of particle therapy in the treatment of prostate cancer. Cancer J. 2009; 15:312-8.

Seco J, Robinson D, Trofimov A, Paganetti H. Breathing interplay effects during proton beam scanning: simulation and statistical analysis. Physics in Medicine and Biology 2009; 54:N283-294.

Vrancic C, Trofimov A, Chan TCY, Sharp G, Bortfeld T. Experimental evaluation of a robust optimization method for IMRT of moving targets. Physics in Medicine and Biology 2009; 54: 2901-2914.

Bortfeld T, Chan TCY, Trofimov A, Tsitsiklis JN. Robust management of motion uncertainty in intensity-modulated radiation therapy. Operations Research 2008; 56:1461-1473

Nguyen PL, Trofimov A, Zietman AL. Proton beam or intensity-modulated therapy in the treatment of prostate cancer? Oncology 2008; 22:748-754.

Trofimov A, Vrancic C, Chan TCY, Sharp GC, Bortfeld T. Tumor trailing startegy for intensity-modulated radiation therapy of moving targets. Medical Physics 2008; 35:1718-1733

MacDonald SM, Safai S, Trofimov A, Wolfgang J, Fullerton B, Yeap BY, Bortfeld T, Tarbell NJ, Yock T. Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. International Journal of Radiation Oncology Biology Physics 2008; 71:979-987

Suit H, Kooy H,Trofimov A, Farr J, Munzenrider J, DeLaney T, Loeffler J, Clasie B, Safai S, Paganetti H. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No. Radiotherapy and Oncology 2008; 86:148-153.

Trofimov A, Nguyen PL, Coen JJ, Doppke KP, Schneider RJ, Adams JA, Bortfeld TR, Zietman AL, DeLaney TF, Shipley WU. Radiotherapy treatment of early stage prostate cancer with IMRT and protons: a treatment planning comparsion. International Journal of Radiation Oncology Biology Physics 2007; 69:444-453 (follow-up: Letter to the Editor. In reply to Ms.Albertini et al. International Journal of Radiation Oncology Biology Physics 2007; 69:1334-1335)

Sharp GC, Lu HM, Trofimov A, Tang X, Jiang SB, Turcotte J, Gierga DP, Chen GTY, Hong TS. Assessing residual motion for gated proton-beam radiotherapy.Journal of Radiation Research 2007; 48:A55-59.

Censor Y, Bortfeld T, Martin B, Trofimov A. A unified approach for inversion problems in intensity-modulated radiation therapy. Physics in Medicine and Biology 2006; 51:2353-65.

Trofimov A, Rietzel E, Lu H, Martin B, Jiang S, Chen G, Bortfeld T. Temporo-spatial IMRT optimization: Concepts, implementation and initial results. Physics in Medicine and Biology 2005; 50:2779-98.

Paganetti H, Jiang H, Trofimov A. 4D Monte Carlo simulation of proton beam scanning: modeling of variations in time and space to study the interplay between scanning pattern and time-dependent patient geometry. Physics in Medicine and Biology 2005; 50:983-90.

DeLaney TF, Trofimov AV, Engelsman M, Suit HD. Advanced-technology radiation therapy in the management of bone and soft tissue sarcomas. Cancer Control 2005; 12:27-35

Weber DC, Trofimov AV, Delaney TF, Bortfeld T. A treatment planning comparison of intensity modulated photon and proton therapy for paraspinal sarcomas. International Journal of Radiation Oncology Biology Physics 2004; 58:1596-606.

Suit H, Goldberg S, Niemierko A, Trofimov A, Adams J, Paganetti H, Chen GTY, Bortfeld T, Rosenthal S, Loeffler J, DeLaney T. Protons to Replace Photon Beams in Radical Dose Treatments. Acta Oncologica 2003; 42:800-8.

Trofimov A, Bortfeld T. Optimization of beam parameters and treatment planning for intensity modulated proton therapy. Technology in Cancer Research and Treatment 2003; 2:437-44.

Trofimov A, Bortfeld T. Beam delivery sequencing for intensity modulated proton therapy. Physics in Medicine and Biology 2003; 48:1321-31.

Publications in High-Energy Physics (with g-2 Collaboration, Brookhaven National Laboratory)

Bennett GW, et al. Improved limit on the muon electric dipole moment. Physical Review D 2009; 80:052008.

Bennett GW et al. Search for Lorentz and CPT violation effects in muon spin precession. Physical Review Letters 2008; 100:091602.

Bennett GW et al Statistical equations and methods applied to the precision muon (g-2) experiment at BNL. Nuclear Instruments and Methods in Physics Research A 2007; 579:1096-1116.

Bennett GW et al. Final report of the E821 muon anomalous magnetic moment measurement at BNL. Physical Review D 2006; 73:072003.

Bennett GW et al. Measurement of the negative muon anomalous moment to 0.7 ppm. Physical Review Letters 2004; 92:161802.

Bennett GW et al. Measurement of the positive muon anomalous moment to 0.7 ppm. Physical Review Letters 2002; 89:101804.

Brown HN et al. Precise measurement of the positive muon anomalous magnetic moment. Physical Review Letters 2001; 86:2227-31.

Sedykh SA et al. Electromagnetic calorimeters for the BNL muon (g-2) experiment. Nuclear Instruments and Methods A 2000; 455:346-60.

Brown HN et al. Improved measurement of the positive muon anomalous magnetic moment. Physical Review D 2000; 62:091101.

Carey RM et al. New measurement of the anomalous magnetic moment of the positive muon. Physical Review Letters 1999; 82:1632-35.

• Program Finder
• Admissions Services
• Course Directory
• Academic Calendar
• Hybrid Campus
• Lecture Series
• Convocation
• Strategy and Development
• Implementation and Impact
• Integrity and Oversight
• In the School
• In the Field
• In Baltimore
• Resources for Practitioners
• Articles & News Releases
• In The News
• Statements & Announcements
• At a Glance
• Student Life
• Strategic Priorities
• Inclusion, Diversity, Anti-Racism, and Equity (IDARE)
• What is Public Health?

Alumni Spotlight: Erjia Cui, PhD '23

Erjia Cui, PhD ’23, is a tenure-track assistant professor in the Division of Biostatistics and Health Data Science at the University of Minnesota. 

Erjia Cui, PhD ’23, is a tenure-track assistant professor in the Division of Biostatistics and Health Data Science at the University of Minnesota.

In March 2024, Erjia co-published the book Functional Data Analysis with R , with Jeff Goldsmith, Andrew Leroux, and his thesis advisor Ciprian Crainiceanu . He has additionally published three papers in the Journal of Computational and Graphical Statistics as the first author.

Describe your current position and responsibilities in a way that will inform current and prospective students about career opportunities in biostatistics.

I am currently an assistant professor in Biostatistics at the University of Minnesota. The goal of my research is to develop novel and reproducible statistical methods such as Functional Data Analysis to help us better understand how physical activity and other biomarkers play a vital role in our daily lives. As modern wearable technology evolves, the data sets we can now collect are becoming more and more complicated. Therefore, the development of computationally feasible methods and corresponding software becomes increasingly important. In addition to my research, I teach graduate level courses for biostatistics students at my institution and provide guidance on their thesis research.

What has been your most satisfying job experience using your biostatistics background?

It is great to see that the functional data analysis methods I developed have been used by other scientists in different fields, including areas I am less familiar with. As mentioned above, I develop software to implement all my statistical methods. It's always rewarding to see people enjoying my software. Additionally, I enjoy sharing my knowledge of biostatistics with students in the classroom or after class and watching them grow into independent biostatisticians.

How did you get interested in the field of biostatistics?

I did my undergraduate training in mathematics and statistics. While they were both very interesting topics and I still love them, there seemed to be a gap between what I learned in class and what happened in real life. After gaining some research experience in biostatistics, I realized that this is a field that uses statistical knowledge to solve real-world problems, which is closely related to my career goals. All these factors led me to apply to graduate school in biostatistics.

The inclusive atmosphere of our department is awesome.

How did your degree in Biostatistics prepare you for your career? What aspects of the Hopkins program did you find most useful?

The PhD training in Biostatistics at Johns Hopkins is very comprehensive. As a PhD student, I spent most of my time doing research and learning different aspects of biostatistics. I started without any background in functional data analysis and learned most of what I knew in the field by reading papers and discussing with my advisors and friends. This helped me develop a deeper understanding of the field and helped me position myself, which I found very helpful when starting my career. Through being a teaching assistant in various classes at Hopkins, I learned how to teach students at different levels. Specifically, I like the PhD-level courses offered by Hopkins, which provide rigorous trainings in probability theory, statistical inference, and statistical methods. These trainings paved the way for my future research, and I found them to be most useful.

What are your favorite memories of your time at Johns Hopkins Biostatistics?

I enjoy discussing different projects and ideas with my advisor Ciprian Crainiceanu and other lab members. I feel like I always learn something from these great people and that is my favorite memory. I also enjoy playing table tennis with my friends at Genome Café where we had a lot of fun. Additionally, the inclusive atmosphere of our department is awesome.

What was your favorite thing about living in Baltimore?

My favorite thing in the Baltimore city is eating blue crabs with friends. Outside the city, Ellicott City has good Korean food.

MORE ALUMNI SPOTLIGHTS

OUR MINISTER

Dr. Joseph Lozovyy was born into a Christian family in Elektrostal, Moscow Region, and was raised in a pastor’s home. From the age of fifteen, he began actively participating in the music ministry of the Baptist Church in Mytishchi, where his father served as a pastor, and also played in the orchestra of the Central Moscow Baptist Church. From 1989, he participated in various evangelistic events in different cities of Moscow Region and beyond. From 1989 to 1992, as a member of the choir and orchestra “LOGOS,” he participated in evangelistic and charitable concerts, repeatedly performing on the stages of the Moscow State Conservatory, the Bolshoi Theatre, and other concert halls in Russia and abroad. In 1992, his family moved to the United States. In 2007, after completing a full course of spiritual and academic preparation, Joseph moved to Dallas, Texas, to engage in church ministry. In 2008, he founded the Russian Bible Church to preach to the Russian-speaking population living in Dallas, Texas.

– Bachelor of Arts in Music (viola) from the Third Moscow Music School named after Scriabin, Russia (1987-1991)

– Master of Theology (Th.M); Dallas Theological Seminary, Texas (1999-2003);

– Doctor of Philosophy (Ph.D) Hebrew Bible (Books of Samuel): University of Edinburgh, Scotland, United Kingdom (2007).

– Doctoral research (2004-2005) Tübingen, Germany.

– Author of a theological work published in English: Saul, Doeg, Nabal and the “Son of Jesse: Readings in 1 Samuel 16-25, LHBOTS 497 [T&T Clark/Continuum: Bloomsbury Publishing]).

https://www.bloomsbury.com/us/saul-doeg-nabal-and-the-son-of-jesse-9780567027535/

Joseph and his wife Violetta and their son Nathanael live in the northern part of Dallas.

Saul, Doeg, Nabal, and the “Son of Jesse”: Readings in 1 Samuel 16-25: The Library of Hebrew Bible/Old Testament Studies Joseph Lozovyy T&T Clark (bloomsbury.com)

Joseph, his wife Violetta and their son Nathaniel live in North Dallas, Texas where he continues ministering to Russian-speaking Christians and his independent accademic research.

Published Work

1. bloomsbury:, 2. buy at christian book distributors:, 3. buy on amazon:.

Victor Mukhin

• Scientific Program

Title : Active carbons as nanoporous materials for solving of environmental problems

However, up to now, the main carriers of catalytic additives have been mineral sorbents: silica gels, alumogels. This is obviously due to the fact that they consist of pure homogeneous components SiO2 and Al2O3, respectively. It is generally known that impurities, especially the ash elements, are catalytic poisons that reduce the effectiveness of the catalyst. Therefore, carbon sorbents with 5-15% by weight of ash elements in their composition are not used in the above mentioned technologies. However, in such an important field as a gas-mask technique, carbon sorbents (active carbons) are carriers of catalytic additives, providing effective protection of a person against any types of potent poisonous substances (PPS). In ESPE “JSC "Neorganika" there has been developed the technology of unique ashless spherical carbon carrier-catalysts by the method of liquid forming of furfural copolymers with subsequent gas-vapor activation, brand PAC. Active carbons PAC have 100% qualitative characteristics of the three main properties of carbon sorbents: strength - 100%, the proportion of sorbing pores in the pore space – 100%, purity - 100% (ash content is close to zero). A particularly outstanding feature of active PAC carbons is their uniquely high mechanical compressive strength of 740 ± 40 MPa, which is 3-7 times larger than that of  such materials as granite, quartzite, electric coal, and is comparable to the value for cast iron - 400-1000 MPa. This allows the PAC to operate under severe conditions in moving and fluidized beds.  Obviously, it is time to actively develop catalysts based on PAC sorbents for oil refining, petrochemicals, gas processing and various technologies of organic synthesis.

Victor M. Mukhin was born in 1946 in the town of Orsk, Russia. In 1970 he graduated the Technological Institute in Leningrad. Victor M. Mukhin was directed to work to the scientific-industrial organization "Neorganika" (Elektrostal, Moscow region) where he is working during 47 years, at present as the head of the laboratory of carbon sorbents.     Victor M. Mukhin defended a Ph. D. thesis and a doctoral thesis at the Mendeleev University of Chemical Technology of Russia (in 1979 and 1997 accordingly). Professor of Mendeleev University of Chemical Technology of Russia. Scientific interests: production, investigation and application of active carbons, technological and ecological carbon-adsorptive processes, environmental protection, production of ecologically clean food.   

Quick Links

• Conference Brochure
• Tentative Program